Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2021 2
2022 4
2023 7
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Central Nervous System Prophylaxis and Treatment in Acute Leukemias.
Wu SY, Short NJ, Nasr L, Dabaja BS, Fang PQ. Wu SY, et al. Among authors: nasr l. Curr Treat Options Oncol. 2022 Dec;23(12):1829-1844. doi: 10.1007/s11864-022-01032-5. Epub 2022 Dec 13. Curr Treat Options Oncol. 2022. PMID: 36510037 Free PMC article. Review.
Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML.
Short NJ, Daver N, Dinardo CD, Kadia T, Nasr LF, Macaron W, Yilmaz M, Borthakur G, Montalban-Bravo G, Garcia-Manero G, Issa GC, Chien KS, Jabbour E, Nasnas C, Huang X, Qiao W, Matthews J, Stojanik CJ, Patel KP, Abramova R, Thankachan J, Konopleva M, Kantarjian H, Ravandi F. Short NJ, et al. Among authors: nasr lf. J Clin Oncol. 2024 May 1;42(13):1499-1508. doi: 10.1200/JCO.23.01911. Epub 2024 Jan 26. J Clin Oncol. 2024. PMID: 38277619 Clinical Trial.
Systemic AL amyloidosis: current approach and future direction.
Bou Zerdan M, Nasr L, Khalid F, Allam S, Bouferraa Y, Batool S, Tayyeb M, Adroja S, Mammadii M, Anwer F, Raza S, Chaulagain CP. Bou Zerdan M, et al. Among authors: nasr l. Oncotarget. 2023 Apr 26;14:384-394. doi: 10.18632/oncotarget.28415. Oncotarget. 2023. PMID: 37185672 Free PMC article. Review.
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents.
Short NJ, Muftuoglu M, Ong F, Nasr L, Macaron W, Montalban-Bravo G, Alvarado Y, Basyal M, Daver N, Dinardo CD, Borthakur G, Jain N, Ohanian M, Jabbour E, Issa GC, Qiao W, Huang X, Kanagal-Shamanna R, Patel KP, Bose P, Ravandi F, Delumpa R, Abramova R, Garcia-Manero G, Andreeff M, Cortes J, Kantarjian H. Short NJ, et al. Among authors: nasr l. J Hematol Oncol. 2023 Jul 8;16(1):73. doi: 10.1186/s13045-023-01476-8. J Hematol Oncol. 2023. PMID: 37422688 Free PMC article. Clinical Trial.
A Synopsis Clonal Hematopoiesis of Indeterminate Potential in Hematology.
Bou Zerdan M, Nasr L, Saba L, Meouchy P, Safi N, Allam S, Bhandari J, Chaulagain CP. Bou Zerdan M, et al. Among authors: nasr l. Cancers (Basel). 2022 Jul 28;14(15):3663. doi: 10.3390/cancers14153663. Cancers (Basel). 2022. PMID: 35954328 Free PMC article. Review.
Adhesion molecules in multiple myeloma oncogenesis and targeted therapy.
Bou Zerdan M, Nasr L, Kassab J, Saba L, Ghossein M, Yaghi M, Dominguez B, Chaulagain CP. Bou Zerdan M, et al. Among authors: nasr l. Int J Hematol Oncol. 2022 Apr 26;11(2):IJH39. doi: 10.2217/ijh-2021-0017. eCollection 2022 Apr. Int J Hematol Oncol. 2022. PMID: 35663420 Free PMC article. Review.
Liquid biopsies and minimal residual disease in lymphoid malignancies.
Bou Zerdan M, Kassab J, Saba L, Haroun E, Bou Zerdan M, Allam S, Nasr L, Macaron W, Mammadli M, Abou Moussa S, Chaulagain CP. Bou Zerdan M, et al. Among authors: nasr l. Front Oncol. 2023 May 9;13:1173701. doi: 10.3389/fonc.2023.1173701. eCollection 2023. Front Oncol. 2023. PMID: 37228488 Free PMC article. Review.
Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL.
Zhao Y, Short NJ, Kantarjian HM, Chang TC, Ghate PS, Qu C, Macaron W, Jain N, Thakral B, Phillips AH, Khoury J, Garcia-Manero G, Zhang W, Fan Y, Yang H, Garris RS, Nasr LF, Kriwacki RW, Roberts KG, Konopleva M, Jabbour EJ, Mullighan CG. Zhao Y, et al. Among authors: nasr lf. medRxiv [Preprint]. 2023 Dec 9:2023.12.06.23299616. doi: 10.1101/2023.12.06.23299616. medRxiv. 2023. PMID: 38106221 Free PMC article. Updated. Preprint.
Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL.
Zhao Y, Short NJ, Kantarjian HM, Chang TC, Ghate PS PhD, Qu C, Macaron W, Jain N, Thakral B, Phillips A, Khoury JD, Garcia-Manero G, Zhang W, Fan Y, Yang H, Garris R, Nasr LF, Kriwacki R, Roberts KG, Konopleva MY, Jabbour EJ, Mullighan CG. Zhao Y, et al. Among authors: nasr lf. Blood. 2024 Mar 29:blood.2024023930. doi: 10.1182/blood.2024023930. Online ahead of print. Blood. 2024. PMID: 38551807
A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia.
Short NJ, Jabbour E, Jain N, Senapati J, Nasr L, Haddad FG, Li Z, Hsiao YC, Yang JJ, Pemmaraju N, Ohanian M, Wierda WG, Montalban-Bravo G, Borthakur G, Han L, Xiao L, Huang X, Abramova R, Zhao M, Garris R, Konopleva M, Ravandi F, Kantarjian H. Short NJ, et al. Among authors: nasr l. Blood Adv. 2024 Feb 27;8(4):909-915. doi: 10.1182/bloodadvances.2023012231. Blood Adv. 2024. PMID: 38207208 Free PMC article. Clinical Trial.
20 results